

Markets Announcement Office  
ASX Limited  
Exchange Centre  
20 Bridge Street  
SYDNEY NSW 2000



ASX ANNOUNCEMENT

**Vitaco shareholders to vote on proposal by entities associated with Shanghai Pharmaceuticals Holdings Co., Ltd and Primavera Capital Fund II L.P. to acquire issued share capital of Vitaco**

Vitaco Holdings Limited (ASX: VIT) ("Vitaco") announces that the Federal Court of Australia has today (26 October 2016) made orders directing Vitaco to convene meetings of its shareholders to consider and vote on the previously announced scheme of arrangement for the proposed acquisition of Vitaco by SIIC Medical Science and Technology (Group) Limited, a 100% subsidiary of Shanghai Pharmaceuticals Holdings Co., Ltd and PV Zeus Limited, a 100% subsidiary of Primavera Capital Fund II L.P. ("Scheme").

The scheme meetings will be held on Wednesday, 30 November 2016 at Northcott Room, SMC Conference & Function Centre, 66 Goulburn Street, Sydney, NSW 2000, commencing at 10.00am (AEDT).

Information relating to the Scheme, including the notices convening the scheme meetings as well as an independent expert's report, will be included in the scheme booklet expected to be sent to Vitaco shareholders on or before Monday, 31 October 2016 ("Scheme Booklet") following registration of the Scheme Booklet by the Australian Securities and Investments Commission ("ASIC").

A further announcement attaching the Scheme Booklet will be released by Vitaco following registration of the Scheme Booklet with ASIC.

***Further Information***

Vitaco shareholders can obtain further information by contacting the Vitaco Shareholder Information Line on 1800 262 299 for shareholders located in Australia, and +61 1800 262 299 for shareholders located outside Australia.

For further information, please contact:

**Investors**

Phil Wiltshire  
Vitaco CFO  
Tel: +64 (0) 275 826 600

**Media**

Peter Brookes  
Citadel-MAGNUS  
Tel: +61 (0) 407 911 389

- Ends -